Is there a role for calcium antagonists when beta-adrenergic blockade therapy is contraindicated in post-myocardial infarction?
Ennezat, P.-V.; Auffray, J.-L.; Darchis, J.; Rousselle, M.; Gonin, X.; Aubert, J.-M.; Bauchart, J.-J.; Bauters, C.; Van Belle, E.; Asseman, P.
Therapie 61(3): 191-194
2006
ISSN/ISBN: 0040-5957 PMID: 16989118 Document Number: 597837
The purpose of this paper is to examine the eventual benefits of treatment with calcium channel blockers in post-myocardial infarction, through an overview of main placebo-controlled trials that have been conducted to test this therapeutic in acute coronary syndromes. It appears obvious that the vast majority of these trials was conducted in the pre-reperfusion era and failed to demonstrate a reduction in mortality. To conclude, the superiority of a therapy with calcium antagonists over a placebo in the management of post-myocardial infarction remains unknown. In contrast, adverse effects associated with the prescription of calcium antagonists are well known.